Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Absorption, Metabolism and Excretion of 14C-olorofim in Man (hAME)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04039880
Recruitment Status : Completed
First Posted : July 31, 2019
Last Update Posted : November 13, 2019
Sponsor:
Collaborator:
PRA Health Sciences
Information provided by (Responsible Party):
F2G Ltd.

Brief Summary:
Single-centre, open-label, non-randomised, single dose study in 2 cohorts of healthy subjects. It is planned to enrol 6 healthy male subjects in Cohort A (standard mass balance and metabolite profiling cohort) and up to 6 subjects in Cohort B (biliary evaluation cohort); each subject will receive a single oral administration of 120 mg [14C]-olorofim oral solution containing approximately 3.7 MBq (100 µCi).

Condition or disease Intervention/treatment Phase
Invasive Fungal Infections Drug: Olorofim Phase 1

Detailed Description:

Subjects will be screened up to 28 days prior to dosing and eligible subjects will be admitted to the Clinical Research Unit (CRU) on the day prior to dosing (Day-1). Each subject will be dosed on the morning of Day 1 after an overnight fast.

Cohort A:

Subjects will remain resident in the CRU up to 336 h post-dose (Day 15), with whole blood, plasma, urine and faeces collected throughout this period. There may be up to two further 24 h residency periods (Days 21 to 22 and Days 28 to 29) for collection of plasma, urine and faeces if discharge criteria are not met.

Cohorts B1 and B2:

Subjects will remain resident in the CRU up to 96 h post-dose (Day 5) for collection of plasma, urine, faeces and bile. Subjects will return for a short follow-up visit on Day 10. Cohort B1 subjects will have bile sampling up to 6 h postdose and Cohort B2 subjects will have bile sampling up to 12 h postdose. Cohort B divided into 2 sub-cohorts for logistical reasons only.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Olorofim Administered Via the Oral Route to Healthy Male Subjects
Actual Study Start Date : July 30, 2019
Actual Primary Completion Date : September 30, 2019
Actual Study Completion Date : September 30, 2019

Arm Intervention/treatment
Experimental: Cohort A (mass balance)
evaluation of mass balance and metabolite profiling
Drug: Olorofim
single oral dose (120 mg, 3.7 MBq)
Other Name: F901318

Experimental: Cohort B (biliary evaluation)
evaluation of biliary elimination
Drug: Olorofim
single oral dose (120 mg, 3.7 MBq)
Other Name: F901318




Primary Outcome Measures :
  1. Mass balance [ Time Frame: 28 days ]
    % dose recovered in urine and faeces

  2. Metabolite profiling [ Time Frame: 15 days ]
    number of metabolites in plasma, urine and faeces > 10% of circulating radioactivity


Secondary Outcome Measures :
  1. biliary elimination [ Time Frame: 5 days ]
    radioactivity present in bile (ug equiv/g)

  2. Maximum plasma concentration (Cmax) for olorofim, F902412 and total radioactivity [ Time Frame: 15 days ]
  3. time of maximum plasma concentration (Tmax) for olorofim, F902412 and total radioactivity [ Time Frame: 15 days ]
  4. elimination half life (t1/2) for olorofim, F902412 and total radioactivity [ Time Frame: 15 days ]
  5. Area under plasma concentration curve (AUC) for olorofim, F902412 and total radioactivity [ Time Frame: 15 days ]
  6. Number of subjects with treatment-related adverse events [ Time Frame: 28 days ]
  7. Number of subjects with clinically significant change from baseline in vital signs, laboratory parameters, and electrocardiogram findings [ Time Frame: 28 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy males age 18 to 55 years of age with body mass index of 18 to 30 kg/m2 (inclusive), and a body weight of 50 to 100 kg (inclusive).
  • Subjects must be in good health as determined by a medical history, physical examination, vital signs, 12-lead ECG and clinical laboratory evaluations (congenital non haemolytic hyperbilirubinaemia is NOT acceptable).
  • Must have regular bowel movements (ie, average stool production of ≥1 and ≤3 stools per day).

Exclusion Criteria:

  • Subjects with or history of clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatry, respiratory, metabolic, endocrine, ocular haematological or other major disorders as determined by the investigator
  • Subjects who have received any prescribed systemic or topical medication within 14 days of the dose administration
  • Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days of the dose administration
  • Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of the dose administration
  • Current smokers and those who have smoked or used nicotine containing products (eg electronic cigarettes) within the 3 months prior to check-in.
  • Radiation exposure, including that from the present study exceeding 1 mSv in the last 12 months or 5 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04039880


Locations
Layout table for location information
Netherlands
PRA Health Sciences
Groningen, Netherlands, 9728
Sponsors and Collaborators
F2G Ltd.
PRA Health Sciences
Investigators
Layout table for investigator information
Principal Investigator: Jan Jaap van Lier, MD PRA
Layout table for additonal information
Responsible Party: F2G Ltd.
ClinicalTrials.gov Identifier: NCT04039880    
Other Study ID Numbers: F901318-01-09
First Posted: July 31, 2019    Key Record Dates
Last Update Posted: November 13, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Mycoses
Invasive Fungal Infections
Olorofim
Antifungal Agents
Anti-Infective Agents